MedTrace Logo

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

NCT05748561 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-28

No results posted yet for this study

Summary

The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4 weeks after therapeutic intervention.

The main question it aims to answer:

• Is there a difference in the visual recovery of toxic optic neuropathies treated with intravenous methylprednisolone in comparison with those treated with intravenous erythropoietin?

Conditions

  • Toxic Optic Neuropathy
  • Treatment
  • Methylprednisolone
  • Erythropoietin

Interventions

DRUG

Recombinant human erythropoietin 4,000 UI and 2,000 UI

Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)

DRUG

Methylprednisolone succinate 500 mg

Intravenous Methylprednisolone succinate (1 g daily for 5 days)

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Jorge Cárdenas-Belaunzarán, MD, MSc · Asociación Para Evitar la Ceguera en México I.A.P

  • Elsa Hernández-Piñamora, MD · Asociación Para Evitar la Ceguera en México I.A.P

  • Octavio Turcio-Aceves, MD · Asociación Para Evitar la Ceguera en México I.A.P

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2024-04-05
Completion
2024-04-05

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05748561 on ClinicalTrials.gov